Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia ( ITP ): Patient and Physician Perceptions From the ITP World Impact Survey (I‐ WISh ) 2.0

Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment-related burden. I-WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients. Approximately one-third of patients reported that ITP had a high impact on daily activities and family/social life, and 54% reported that it had a high impact on emotional wellbeing. Patients and physicians generally aligned on symptoms and treatment goals, but more patients (48%) than physicians (29%) reported fatigue as common and problematic. Ninety-seven percent of patients reported that they had received treatment for ITP, most commonly corticosteroids. Most patients and 54% of physicians were satisfied with available treatments, although patients reported treatment-related burdens. Twenty-eight percent confirmed they would have chosen a different treatment. Two-thirds of patients were in a stable, sustained remission, and most had never paused treatment (67%). Nevertheless, two-thirds of patients preferred limiting time on treatment and/or not being on lifelong treatment. I-WISh 2.0 emphasizes the extensive disease and treatment burden faced by patients living with ITP, especially the impact of fatigue. It also reminds us that shared decision-making is needed to ensure treatment goals are aligned with patient expectations, including health-related quality of life.